论文部分内容阅读
CytoDyn公司报告PRO 140单药治疗11名艾滋患者Ⅱb期临床试验,每周自身皮下给药1次/周,14~17个月获病毒学全抑制,用敏感的单拷贝HIV-1 RNA检测,有7名血中艾滋病毒RNA水平<1拷贝/ml,最低者0.4拷贝/ml。Ⅱb期临床试验已在2015年1月完成,病毒全抑制患者其后13周治疗为患者自身皮下给药,双周监测1次直至60周,患者耐受良好,无因不良反应而停药者。PRO 140是长效艾滋病毒抑制剂,保护健康
CytoDyn reports the PRO 140 monotherapy of 11 AIDS patients in Phase IIb clinical trials with subcutaneous self-administration of 1 x week weekly and full virological inhibition of 14 to 17 months with sensitive single-copy HIV-1 RNA, Seven blood HIV RNA levels <1 copy / ml, the lowest 0.4 copies / ml. Ⅱb clinical trial was completed in January 2015, the virus fully suppressed patients after 13 weeks of treatment for patients with subcutaneous self-administered, bi-weekly monitoring up to 60 weeks, patients were well tolerated, no due to adverse reactions and withdrawal . PRO 140 is a long-acting HIV inhibitor that protects your health